Patents by Inventor Jeffrey Engler

Jeffrey Engler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080166293
    Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
    Type: Application
    Filed: February 18, 2008
    Publication date: July 10, 2008
    Inventors: Jeffrey A. Engler, Jae Hwy Lee, James F. Collawn, Bryan A. Moore
  • Publication number: 20070066801
    Abstract: Novel reagents capable of identifying, or aiding in the identification of, Francisella strains, such as, but not limited to, those identified in playing a role in human diseases or those identified as capable of being used as a biological weapon, are disclosed. In addition, methods for the identification and isolation of the reagents are disclosed. In one embodiment the reagents are peptide sequences. The reagents may be used in diagnostic assays and kits to diagnose the presence of such Francisella strains. In addition the agents identified may be used as research tools for the study and characterization of such Francisella strains.
    Type: Application
    Filed: July 14, 2004
    Publication date: March 22, 2007
    Inventors: Jeffrey Engler, Vincent Escuyer
  • Publication number: 20060193778
    Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
    Type: Application
    Filed: March 23, 2004
    Publication date: August 31, 2006
    Inventors: Jeffrey Engler, Jae Lee, James Collawn, Bryan Moore
  • Patent number: 6743893
    Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: June 1, 2004
    Assignee: The UAB Research Foundation
    Inventors: Jeffrey A. Engler, Jae Hwy Lee, James F. Collawn, Bryan A. Moore
  • Publication number: 20040081646
    Abstract: The present disclosure relates to the identification phage lysin from group B streptococci (GBS). The nucleic acid sequence and amino acid sequence of the GBS phage lysin is disclosed. The GBS phage lysin is a bifunctional protein comprising a glucosidase and an endopeptidease activity. The endopeptidase present in the GBS phage lysis has a substrate specificity that has not been previously reported. The bifunctional GBS phage lysin is effective against groups A, B, C, E and G streptococci. Also described are methods of using the GBS phage lysin for the prevention and treatment of bacterial infections.
    Type: Application
    Filed: August 28, 2003
    Publication date: April 29, 2004
    Inventors: Jeffrey A. Engler, Jane R. Schwebke, John R. Baker, David G. Pritchard
  • Patent number: 6683170
    Abstract: The fiber protein of adenovirus has been genetically altered via attachment at the carboxyl end of a peptide linker, preferably up to 26 amino acids in length which forms a random coil, which can be used to attach a non-adenovirus ligand altering the binding specificity of the fiber protein. Examples of ligands include peptides which are selectively bound by a targeted cell so that the modified fiber protein is internalized by receptor-mediated endocytosis, and peptides which can act as an universal coupling agent, for example, biotin or strepavidin. The linker is designed to not interfere with normal trimerization of fiber protein, to avoid steric hindrance of binding of the fiber protein to a targeted cell, and to serve as a site to introduce new peptide sequence.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: January 27, 2004
    Assignee: UAB Research Foundation
    Inventors: David T. Curiel, Jeffrey A. Engler
  • Publication number: 20020115824
    Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
    Type: Application
    Filed: November 29, 2001
    Publication date: August 22, 2002
    Inventors: Jeffrey A. Engler, Jae Hwy Lee, James F. Collawn, Bryan A. Moore
  • Publication number: 20020076419
    Abstract: The fiber protein of adenovirus has been genetically altered via attachment at the carboxyl end of a peptide linker, preferably up to 26 amino acids in length which forms a random coil, which can be used to attach a non-adenovirus ligand altering the binding specificity of the fiber protein. Examples of ligands include peptides which are selectively bound by a targeted cell so that the modified fiber protein is internalized by receptor-mediated endocytosis, and peptides which can act as an universal coupling agent, for example, biotin or strepavidin. The linker is designed to not interfere with normal trimerization of fiber protein, to avoid steric hindrance of binding of the fiber protein to a targeted cell, and to serve as a site to introduce new peptide sequence. The modified fiber protein is prepared by genetic engineering of the nucleotide sequence encoding the fiber protein, through the addition of new sequence at the carboxyl tail-encoding region which encodes the linker and the ligand.
    Type: Application
    Filed: July 13, 2001
    Publication date: June 20, 2002
    Applicant: UAB Research Foundation
    Inventors: David T. Curiel, Jeffrey A. Engler
  • Patent number: 6312699
    Abstract: The fiber protein of adenovirus has been genetically altered via attachment at the carboxyl end of a peptide linker, preferably up to 26 amino acids in length which forms a random coil, which can be used to attach a non-adenovirus ligand altering the binding specificity of the fiber protein. Examples of ligands include peptides which are selectively bound by a targeted cell so that the modified fiber protein is internalized by receptor-mediated endocytosis, and peptides which can act as an universal coupling agent, for example, biotin or strepavidin. The linker is designed to not interfere with normal trimerization of fiber protein, to avoid steric hindrance of binding of the fiber protein to a targeted cell, and to serve as a site to introduce new peptide sequence. The modified fiber protein is prepared by genetic engineering of the nucleotide sequence encoding the fiber protein, through the addition of new sequence at the carboxyl tail-encoding region which encodes the linker and the ligand.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: November 6, 2001
    Assignee: UAB Research Foundation
    Inventors: David T. Curiel, Jeffrey A. Engler
  • Patent number: D761625
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: July 19, 2016
    Assignee: Boelter Brands, LLC
    Inventors: Jeffrey Engler, Jay Wilcox
  • Patent number: D789156
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 13, 2017
    Assignee: BOELTER BRANDS, LLC
    Inventors: Jeffrey Engler, Jay Wilcox